Praxis precision medicines provides update on essential3 and corporate update

Boston, feb. 28, 2025 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on the interim analysis for study 1 of the essential3 program of ulixacaltamide in essential tremor (et), an update on other therapies in development and a financial update.
PRAX Ratings Summary
PRAX Quant Ranking